Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Psyence Group Inc C.PSYG

Alternate Symbol(s):  PSYGF

Psyence Group Inc., a life science biotechnology company, engages in the research, cultivation, and production of psychedelics and nature-based compounds to treat psychological trauma. It operates in two segments, Clinical Trial Activities and Non-Clinical Trial Activities. The company develops botanical psilocybin-based psychedelic medicine, which works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. It also focuses on the research and development, cultivation, and production of psilocybin mushrooms and functional over-the-counter mushroom products. The company offers its functional mushroom products under the GOODMIND brand. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.


CSE:PSYG - Post by User

Post by SEEdgaron Feb 04, 2021 4:26am
544 Views
Post# 32467706

Psyence Group Presenting at Canaccord Genuity Conference

Psyence Group Presenting at Canaccord Genuity ConferenceArticles@nasdaq/psyence-group-presenting-at-canaccord-genuity-conference channel 1 online Today This week by @nasdaq on 3 Feb 2021, 18:15 Psyence Group Presenting at Canaccord Genuity Conference "New Paradigms & Treatment Approaches in Mental Health" TORONTO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (Psyence or the Company) is pleased to announce that its Co-founder and CEO, Jody Aufrichtig will be presenting at the Canaccord Genuity conference "New Paradigms & Treatment Approaches in Mental Health", being held tomorrow, February 4, 2021 at 9am EST. Direct Webcast Link: https://wsw.com/webcast/canaccord50/psy/2291892 Psyence Group is pioneering the use of natural psilocybin for the long-term treatment of trauma and its mental health consequences. The Companys global footprint operates across multiple legal jurisdictions, through the advanced provision of psychedelic therapy and experience, as well as market leading functional mushroom brands and product portfolio.
<< Previous
Bullboard Posts
Next >>